Business Context and Reporting Period
Company: Archimedes Tech SPAC Partners II Co.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter ended September 30, 2025
Business Overview: A Cayman Islands blank check company formed on June 7, 2024, to effect a business combination with one or more technology companies (specifically AI, cloud services, and automotive technology). The Company consummated its Initial Public Offering (IPO) on February 12, 2025, and has not yet selected a target business. It is classified as an emerging growth company and a shell company.
Key Financial Metrics
| Metric | Value (as of/for period ended Sept 30, 2025) |
|---|---|
| Total Assets | $239,270,951 |
| Cash Held in Trust Account | $237,491,299 |
| Cash (Outside Trust) | $1,409,116 |
| Total Liabilities | $8,178,569 |
| Deferred Underwriting Fee | $8,050,000 |
| Net Income (3 Months) | $2,403,801 |
| Net Income (9 Months) | $5,921,602 |
| Operating Expenses (3 Months) | $159,842 |
| Operating Expenses (9 Months) | $467,299 |
| Shares Outstanding (Public) | 23,000,000 |
| Shares Outstanding (Founder/Private) | 6,590,000 |
Material Changes vs. Prior Period
- Capitalization Event: The most significant change is the consummation of the IPO on February 12, 2025. Total assets increased from $429,691 at December 31, 2024, to $239.3 million at September 30, 2025, driven by the deposit of $231.15 million into the Trust Account.
- Profitability Shift: The Company transitioned from a net loss of $13,000 for the three months ended September 30, 2024, to a net income of $2.4 million for the same period in 2025. This is primarily due to interest income earned on the Trust Account ($2.55 million) and operating bank accounts, which did not exist in the prior period.
- Liabilities: Current liabilities decreased from $483,391 to $128,569 as the promissory note to the related party was repaid upon the IPO closing. However, a new non-current liability of $8.05 million was recorded for the deferred underwriting fee.
- Share Structure: 23,000,000 public shares were issued and classified as temporary equity (subject to redemption), whereas no such shares existed at the end of 2024.
Outlook, Risks, and Management Commentary
- Business Combination Deadline: The Company has 21 months from the IPO closing (February 12, 2025) to complete a business combination. If unsuccessful, the Company will liquidate and redeem public shares.
- Liquidity: Management intends to use the $1.4 million held outside the Trust Account for working capital, due diligence, and transaction costs. The Sponsor has agreed to loan funds if necessary to meet working capital deficiencies, with up to $1.5 million convertible into units.
- Redemption Rights: Public shareholders may redeem their shares for a pro rata portion of the Trust Account (approx. $10.33 per share as of Sept 30, 2025) upon the completion of a business combination or if the Company fails to complete one within the deadline.
- Risks: The filing highlights risks associated with early-stage companies, the inability to complete a business combination, and potential dilution. Geopolitical instability and market downturns are cited as factors that could adversely affect the search for a target.
- Unusual Items: Net income is non-operating in nature, derived almost entirely from interest on Trust Account funds. Operating expenses remain low as the Company is in the pre-merger phase.
Investor Verification Checklist
- Trust Account Balance: Verify the current balance of $237.5 million and the per-share redemption value of $10.33.
- Deferred Underwriting Fee: Confirm the $8.05 million liability payable only upon successful completion of a business combination.
- Extension Options: Review the Company's charter for provisions allowing shareholders to vote to extend the 21-month completion window.
- Related Party Transactions: Monitor the $10,000 monthly administrative fee paid to the Sponsor and any potential working capital loans.
- Warrant Terms: Note the 11.92 million outstanding warrants (Public and Private) with an exercise price of $11.50, which are currently anti-dilutive.